2023 World Conference on Lung Cancer (Posters)-P1.21. Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy

P1.21. Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

A recent study investigated the potential of serum glycoproteomics as a predictive biomarker for immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) therapy. The study included 47 NSCLC patients who received ICI therapy and analyzed their pretreatment blood samples using liquid chromatography and mass spectrometry. A total of 532 glycopeptides from 75 serum proteins were extracted and analyzed, and 22 glycopeptides showed significant differences between patients with and without irAEs. These 22 glycopeptides were used to create a glycoproteomics signature that classified patients into two groups (Group A and Group B), and it was found that the proportion of patients with irAEs was higher in Group B. Furthermore, there was a statistically significant difference between the two groups in the development of irAEs. However, the glycoproteomics signature did not predict the response or survival to ICI treatment. These findings suggest that pretreatment glycoproteomics patterns may be useful in predicting the development of irAEs in NSCLC patients undergoing ICI therapy. Further validation of this model with a larger cohort is needed.

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

serum glycoproteomics

predictive biomarker

immune-related adverse events

non-small cell lung cancer

immune checkpoint inhibitors

liquid chromatography

mass spectrometry

glycopeptides

glycoproteomics signature

irAEs